1
|
Ricci F, Masini F, Fossati B, Frascione P, De Waure C, Capizzi R, Guerriero C. Combination therapy with hydrogen peroxide (4%), salicylic acid (0.5%) and D-panthenol (4%): efficacy and skyn tolerability in common acne vulgaris during sun exposure period. Eur Rev Med Pharmacol Sci 2016; 20:232-236. [PMID: 26875890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
OBJECTIVE Acne vulgaris is a disease of the sebaceous follicle which affects up to 90% of adolescent patients. Topical retinoids, benzoyl peroxide and antibiotics are the main treatments for mild to moderate acne vulgaris. The use of such topical treatments is often associated with local irritation and dryness making the skin more sensitive to the sun. The aim of our study was to assess the efficacy and skin tolerability of a fixed-dose combination therapy with hydrogen peroxide (4%), Salicylic acid (0.5%) and D-panthenol (4%) (HSD) gel, in mild-moderate acne vulgaris, during the period of sun exposure. PATIENTS AND METHODS We retrospectively observed 30 patients of Central Italy with mild to moderate acne between April and September 2012. All the patients selected underwent only therapy with HSD gel once a day in the evening for 60 days, while in the morning they just applied SPF 50 sunscreen. We evaluate the efficacy at 30 and 60 days with the "Global Evaluation Scale" (GES) and the tolerability with a 0-3 qualitative scale. RESULTS The mean GES value showed a statistically significant reduction: 2.03 (SD 0.81) at baseline, 1.63 (SD 0.81) and 0.90 (SD 0.71) respectively at 30 and 60 days (p < 0.01). 21 (70%) and 27 patients (90%) did show good or very good tolerability at 30 and 60 days respectively. CONCLUSIONS Topical treatments with retinoids, antibiotics and antiseptics may increase skin irritation reducing patient adherence to the treatment. HSD gel has shown a good skin tolerability and efficacy in reducing acne lesions, even during the sun exposure period in which traditional treatments should be cautiously used.
Collapse
Affiliation(s)
- F Ricci
- Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|
2
|
Garcovich S, Di Stefani A, Capizzi R, Massi G, Peris K. Occurrence of hidradenitis suppurativa and phrynoderma after bariatric surgery. J Eur Acad Dermatol Venereol 2015; 30:1215-7. [PMID: 25879252 DOI: 10.1111/jdv.13140] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- S Garcovich
- Institute of Dermatology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Di Stefani
- Institute of Dermatology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - R Capizzi
- Institute of Dermatology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - G Massi
- Institute of Pathology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - K Peris
- Institute of Dermatology, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
3
|
Garcovich S, Migaldi M, Reggiani Bonetti L, Capizzi R, Massimo L, Boninsegna A, Arena V, Cufino V, Scannone D, Sgambato A. Loss of alpha-dystroglycan expression in cutaneous melanocytic lesions. J Eur Acad Dermatol Venereol 2015; 30:1031-3. [PMID: 25765870 DOI: 10.1111/jdv.13087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- S Garcovich
- Institute of Dermatology, A. Gemelli University Hospital, Università Cattolica del Sacro Cuore, Rome, Italy
| | - M Migaldi
- Department of Pathology, Università di Modena e Reggio Emilia, Modena, Italy
| | - L Reggiani Bonetti
- Department of Pathology, Università di Modena e Reggio Emilia, Modena, Italy
| | - R Capizzi
- Institute of Dermatology, A. Gemelli University Hospital, Università Cattolica del Sacro Cuore, Rome, Italy
| | - L Massimo
- Department of Pathology, Università di Modena e Reggio Emilia, Modena, Italy
| | - A Boninsegna
- Institute of General Pathology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - V Arena
- Institute of Pathology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - V Cufino
- Institute of General Pathology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - D Scannone
- Institute of General Pathology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Sgambato
- Institute of General Pathology, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
4
|
Vendittelli F, Paolillo C, Autilio C, Lavieri MM, Silveri SL, Capizzi R, Capoluongo E. Absolute quantitative PCR for detection of molecular biomarkers in melanoma patients: a preliminary report. Clin Chim Acta 2015; 444:242-9. [PMID: 25727516 DOI: 10.1016/j.cca.2015.02.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2015] [Revised: 02/05/2015] [Accepted: 02/05/2015] [Indexed: 11/18/2022]
Abstract
BACKGROUND Malignant melanoma is the most malignant tumours of skin and mucous membranes mainly due to its aggressive biological behaviour and tendency to generate early metastases. Unfortunately, the mechanisms underlying the development, progression and the expression of an aggressive melanoma phenotype still remain largely unknown. OBJECTIVES The purpose of this study was to determine whether a multi-panel of molecular transcripts can be predictive for risk of recurrent disease in malignant melanoma patients. RESULTS Peripheral blood was collected from 31 malignant melanoma patients in follow-up for melanoma and from 30 healthy volunteers randomly selected. Each specimen was examined by qRT-PCR analysis for the expression of six markers: PAX3d, TYR, MITFm, MCAM, TGFβ2 and ABCB5. Malignant melanoma patients expressed an important number of markers, with a median value of four markers. Only PAX3d displayed a trend in terms of differences when the levels of gene expression were made in function of Breslow index. Furthermore, PAX3d showed the best diagnostic capacity among the remaining residual markers or in combination with TGFβ2 and MTIF. CONCLUSIONS We demonstrated the usefulness of multimarker qRT-PCR to detect circulating melanoma cells in blood and to potentially assessing patient disease status or progression, especially when PAX3d was used in combination with MTIFm and TGFβ2.
Collapse
Affiliation(s)
- F Vendittelli
- Laboratory of Clinical Molecular and Personalized Diagnostics, Department of Biochemistry and Clinical Biochemistry, Catholic University, Rome, Italy
| | - C Paolillo
- Laboratory of Clinical Molecular and Personalized Diagnostics, Department of Biochemistry and Clinical Biochemistry, Catholic University, Rome, Italy
| | - C Autilio
- Laboratory of Clinical Molecular and Personalized Diagnostics, Department of Biochemistry and Clinical Biochemistry, Catholic University, Rome, Italy
| | - M M Lavieri
- Unit of Dermatology, Cristo Re Hospital, Rome, Italy
| | - S L Silveri
- Department of Dermatology, Catholic University of Rome, Rome, Italy
| | - R Capizzi
- Department of Dermatology, Catholic University of Rome, Rome, Italy
| | - E Capoluongo
- Laboratory of Clinical Molecular and Personalized Diagnostics, Department of Biochemistry and Clinical Biochemistry, Catholic University, Rome, Italy.
| |
Collapse
|
5
|
Fava P, Astrua C, Chiarugi A, Crocetti E, Pimpinelli N, Fargnoli MC, Maurichi A, Rubegni P, Manganoni AM, Bottoni U, Catricalà C, Cavicchini S, Santinami M, Alaibac M, Annetta A, Borghi A, Calzavara Pinton P, Capizzi R, Clerico R, Colombo E, Corradin MT, De Simone P, Fantini F, Ferreli C, Filosa G, Girgenti V, Giulioni E, Guarneri C, Lamberti A, Lisi P, Nardini P, Papini M, Peris K, Pizzichetta MA, Salvini C, Savoia P, Strippoli D, Tolomio E, Tomassini MA, Vena GA, Zichichi L, Patrizi A, Argenziano G, Simonacci M, Quaglino P. Differences in clinicopathological features and distribution of risk factors in Italian melanoma patients. Dermatology 2015; 230:256-62. [PMID: 25659983 DOI: 10.1159/000368775] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Accepted: 09/29/2014] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND No studies are available in the literature on the distribution of different melanoma features and risk factors in the Italian geographical areas. OBJECTIVE To identify the differences in clinical-pathological features of melanoma, the distribution of risk factors and sun exposure in various Italian macro-areas. METHODS Multicentric-observational study involving 1,472 melanoma cases (713 north, 345 centre, 414 south) from 26 referral centres belonging to the Italian Multidisciplinary Group for Melanoma. RESULTS Melanoma patients in northern regions are younger, with thinner melanoma, multiple primaries, lower-intermediate phototype and higher counts of naevi with respect to southern patients; detection of a primary was mostly connected with a physician examination, while relatives were more involved in the south. Northern patients reported a more frequent use of sunbeds and occurrence of sunburns before melanoma despite sunscreen use and a lower sun exposure during the central hours of the day. CONCLUSIONS The understanding of differences in risk factors distribution could represent the basis for tailored prevention programmes.
Collapse
Affiliation(s)
- P Fava
- Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Masini F, Ricci F, Fossati B, Frascione P, Capizzi R, De Waure C, Guerriero C. Combination therapy with retinaldehyde (0.1%) glycolic acid (6%) and efectiose (0.1%) in mild to moderate acne vulgaris during the period of sun exposure--efficacy and skin tolerability. Eur Rev Med Pharmacol Sci 2014; 18:2283-2286. [PMID: 25219827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
OBJECTIVES Acne vulgaris is the most common disease of the adolescence age (70-94%). Main topical treatments for acne vulgaris are retinoids, benzoyl peroxide and antibiotics in mono or combination therapy. Topical retinoids, some antibiotics and antiseptics although effective on acne lesions, can due photosensitivity or make the skin more sensitive to the sun. Our study is aimed to evaluate the efficacy and tolerability of a combination therapy with Retinaldheyde (0.1%), Glycolic acid (6%) and Efectiose (0.1%) (RGE) cream in patients affected by acne vulgaris, during the lasting period of sun exposure. PATIENTS AND METHODS We retrospectively observed 30 patients of Central Italy with mild or moderate acne between April and September. All the patients selected underwent only therapy with RGE cream once a day in the evening for 8 weeks, while in the morning they just applied SPF 50 sunscreen. We evaluate the efficacy at 30 and 60 days with the "Global Evaluation Scale" (GES) and the tolerability with a 0-3 qualitative scale. RESULTS The mean GES value showed a statistically significant reduction: 1.83 (SD 0.83) at baseline 1.57 (SD 0.77) and 0.90 (SD 0.76) respectively at 30 and 60 days (p < 0.01). Side effects were very uncommon. CONCLUSIONS Topical treatments with retinoids, antibiotics and antiseptics can be associated with an increased occurrence of facial dryness and erythema restricting their use in sun exposure period. RGE cream has shown a good skin tolerability and efficacy, so it can be considerate an effective maintaining therapy to treat mild to moderate acne during the sun exposure period in which retinoids, antibiotics or antiseptic treatments are not recommended.
Collapse
Affiliation(s)
- F Masini
- Department of Dermatology, Catholic University of the Sacred Heart, School of Medicine, Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|
7
|
Argenziano G, Moscarella E, Annetta A, Battarra VC, Brunetti B, Buligan C, Cantisani C, Capizzi R, Carbone A, Carlino A, Corsetti V, Damiano A, De Salvo V, De Simone P, Di Caterino P, Fargnoli MC, Ferrari A, Fossati B, Frascione P, Ghigliotti G, González Inchaurraga MA, Guerriero C, Landi C, Mazzoni L, Mirizzi S, Palazzo G, Pedretti A, Peris K, Piemonte P, Rossi A, Satta R, Savoia F, Scalvenzi M, Stanganelli I, Stinco G, Zampieri P, Zalaudek I. Melanoma detection in Italian pigmented lesion clinics. GIORN ITAL DERMAT V 2014; 149:161-166. [PMID: 24819635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM Accuracy in melanoma detection is important to recognize early curable melanomas and to minimize the unnecessary excision of benign lesions. The aim of this paper was to evaluate melanoma screening accuracy of Italian pigmented lesion clinics in terms of number needed to excise (NNE), melanoma thickness, and number of melanomas diagnosed during patient follow-up. METHODS Information on all skin tumors excised in 2011 were extracted from the databases of the participating centers. Information whether the lesion was excised at the baseline examination or during patient follow-up was recorded, as well as the overall number of patients examined in each center in 2011. RESULTS After e-mail solicitation, 22 of 40 centers agreed to participate. A total of 8229 excised lesions were collected. The overall number of examined patients was 86.564, thus 9.5% of screened patients had a lesion removed. Of the excised lesions, 866 were diagnosed as melanoma (1% of examined patients) and 5311 (88.9%) were melanocytic nevi. Three NNE were calculated giving values of 7.9 excised lesions to find 1 melanoma, 7.1 melanocytic lesions to find 1 melanoma, and 3.7 lesions to find 1 skin malignancy. The median melanoma thickness was 0.6 mm, with only 15.1% of melanomas ≥ 1 mm of thickness. Melanomas detected over time were 96 (11.1%; mean thickness, 0.3 mm), with 15.6% of lesions excised after short-term follow-up and 84.4% after long-term follow-up. CONCLUSION The NNE values comparable to those achieved in specialized clinical settings and the high number of early melanomas diagnosed at the baseline examination or during patient follow-up indicate a high level of accuracy in melanoma screening achieved by Italian pigmented lesion clinics.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Ambulatory Care Facilities/statistics & numerical data
- Carcinoma, Basal Cell/diagnosis
- Carcinoma, Basal Cell/epidemiology
- Carcinoma, Basal Cell/surgery
- Carcinoma, Squamous Cell/diagnosis
- Carcinoma, Squamous Cell/epidemiology
- Carcinoma, Squamous Cell/surgery
- Dermatology/organization & administration
- Dermoscopy
- Early Detection of Cancer
- Female
- Follow-Up Studies
- Humans
- Italy/epidemiology
- Keratosis, Seborrheic/diagnosis
- Keratosis, Seborrheic/epidemiology
- Keratosis, Seborrheic/surgery
- Male
- Melanoma/diagnosis
- Melanoma/epidemiology
- Melanoma/pathology
- Melanoma/surgery
- Middle Aged
- Neoplasm Grading
- Nevus, Pigmented/diagnosis
- Nevus, Pigmented/epidemiology
- Nevus, Pigmented/pathology
- Nevus, Pigmented/surgery
- Skin Neoplasms/diagnosis
- Skin Neoplasms/epidemiology
- Skin Neoplasms/pathology
- Skin Neoplasms/surgery
- Young Adult
Collapse
Affiliation(s)
- G Argenziano
- Skin Cancer Unit Arcispedale Santa Maria Nuova IRCCS Reggio Emilia, Italy -
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Guerriero C, Perino F, Favoriti N, Capizzi R, Sani I, Rigante D. Paracetamol-induced hypersensitivity vasculitis in a 10-year-old child. Eur Rev Med Pharmacol Sci 2013; 17:3405-3406. [PMID: 24379075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- C Guerriero
- Department of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.
| | | | | | | | | | | |
Collapse
|
9
|
Mok T, Nakagawa K, Rosell R, Wu YL, Trygstad C, Capizzi R, DeBenedetto R, Goldberg Z, Wang T, Antic V. Phase 3 Randomized Study (ARCHER 1050) of 1st-Line Dacomitinib vs Gefitinib for Advanced NSCLC with EGFR Mutation(S). Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.58] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Mok T, Nakagawa K, Rosell R, Wu Y, Trygstad C, Capizzi R, DeBenedetto R, Goldberg Z, Wang T, Antic V. 92P ARCHER 1050: PHASE III RANDOMIZED STUDY OF 1ST-LINE DACOMITINIB (D) VS GEFITINIB (G) FOR ADVANCED (ADV) NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS (PTS) WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION(S). Lung Cancer 2013. [DOI: 10.1016/s0169-5002(13)70311-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Isambert N, Campone M, Bourbouloux E, Drouin M, Major A, Yin W, Loadman P, Capizzi R, Grieshaber C, Fumoleau P. Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours. Eur J Cancer 2010; 46:729-34. [DOI: 10.1016/j.ejca.2009.12.005] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2009] [Accepted: 12/01/2009] [Indexed: 11/16/2022]
|
12
|
|
13
|
Guerriero C, Manco S, Paradisi A, Capizzi R, Fossati B, Fabrizi G. Extragenital Lichen Sclerosus and Atrophicus Treated with Topical Steroids and Retinoids in a Child with Vitiligo. Int J Immunopathol Pharmacol 2008; 21:757-9. [DOI: 10.1177/039463200802100333] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Lichen sclerosus and atrophicus (LSA) most commonly affects the anogenital region. Extragenital involvement is rare, and women are reported to be affected 6 to 10 times more often than men. The aetiology of LSA is unclear, but genetic, physiological and environmental factors are thought to be involved. Several lines of evidence support the hypothesis of an autoimmune basis for LSA; an increased incidence of tissue-specific antibodies and an association with autoimmune disorders such as vitiligo, alopecia areata, thyroid disease and pernicious anaemia have been reported. We describe a paediatric patient with extragenital LSA associated with vitiligo who was successfully treated with topical steroids and retinoids.
Collapse
Affiliation(s)
| | | | | | | | | | - G. Fabrizi
- Department of Dermatology, University of Molise School of Medicine, Campobasso, Italy
| |
Collapse
|
14
|
|
15
|
Ojetti V, Aguilar Sanchez JA, De Simone C, Migneco A, Capizzi R, Schiavino D, Nucera E, Patriarca G, Gasbarrini G, Gasbarrini A. The role of immune serological parameters and allergological tests in psoriasis. J Eur Acad Dermatol Venereol 2008; 22:621-2. [DOI: 10.1111/j.1468-3083.2007.02432.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Guerriero C, Lanza Silveri S, Sisto T, Rosati D, De Simone C, Fossati B, Pomini F, Rotoli M, Amerio P, Capizzi R. Impetigo herpetiformis occurring during N-butyl-scopolammonium bromide therapy in pregnancy: case report. J BIOL REG HOMEOS AG 2008; 22:141-144. [PMID: 18597707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Impetigo herpetiformis (IH) is a rare dermatosis arising during the third trimester of pregnancy which is generally considered as a form of pustular psoriasis of unknown aetiology. Clinically it is characterized by erythematous plaques surrounded by sterile pustules associated with fever, diarrhea, sweating and increasing risk of stillbirth for placental insufficiency. We describe a case of developed erythematous plaques surrounded by pustules localised initially to the trunk of a 35-year-old woman at the 34th week of gestation after 5 days of treatment with N-Butyl-Scopolammonium, and which later involved the upper and lower limbs. Skin histology confirmed the diagnosis of generalised pregnancy pustular psoriasis (impetigo herpetiformis). IH is reported to be associated with hypocalcemia, hypoparathyroidism, use of oral contraceptives and bacterial infections. This is the first report suggesting the potential role of drugs other than oral contraceptives in the pathogenetic mechanism of this disease. In this case an adverse cutaneous reaction to BB could be the cause of the development of Koebner isomorphism.
Collapse
|
17
|
Paradisi A, Guidi B, Diociaiuti A, Forni F, Scribano D, Sisto T, Amerio PL, Capizzi R. Increased S100B protein serum levels in psoriasis. J Dermatol Sci 2007; 48:148-50. [PMID: 17719207 DOI: 10.1016/j.jdermsci.2007.07.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2007] [Revised: 07/04/2007] [Accepted: 07/12/2007] [Indexed: 11/28/2022]
|
18
|
Amerio P, Tracanna M, De Remigis P, Betterle C, Vianale L, Marra ME, Di Rollo D, Capizzi R, Feliciani C, Tulli A. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4. Clin Exp Dermatol 2007; 31:746-9. [PMID: 16803462 DOI: 10.1111/j.1365-2230.2006.02171.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Vitiligo is a common skin disease characterized by depigmented maculae resulting from a reduction of the number and function of melanocytes. Many studies suggest that vitiligo might be an autoimmune disease. Vitiligo has been frequently described in association with other autoimmune diseases. Among the diseases described in association with vitiligo are the so-called autoimmune polyglandular syndromes (APS). Vitiligo can be present in all types of APS but the most frequent association appears to be in APS-3. APS-3 was defined as the association between autoimmune thyroiditis and another autoimmune disease. Here we report one patient with thyroiditis, vitiligo and autoimmune gastritis (APS-3B+C), one patient with chronic autoimmune thyroiditis, vitiligo and alopecia (APS-3C), and one case of a young patient with type 1 diabetes mellitus and vitiligo (APS-4), according to the newest classification. We stress the importance of a thorough assessment for autoimmune diseases in selected patients with vitiligo.
Collapse
Affiliation(s)
- P Amerio
- Department of Dermatology, University of Chieti-Pescara, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
|
20
|
Santonocito C, Capizzi R, Concolino P, Lavieri MM, Paradisi A, Gentileschi S, Torti E, Rutella S, Rocchetti S, Di Carlo A, Di Stasio E, Ameglio F, Zuppi C, Capoluongo E. Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism. Br J Dermatol 2007; 156:277-82. [PMID: 17223867 DOI: 10.1111/j.1365-2133.2006.07620.x] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Literature data report an association between some vitamin D receptor (VDR) polymorphisms and different kinds of tumours, including malignant melanoma (MM). Only three VDR polymorphisms (FokI, TaqI and A-1012G) have been investigated in association with the presence of cutaneous MM or the development of metastases. OBJECTIVES The present paper analyses for the first time the association between BsmI polymorphism and MM prevalence together with Breslow thickness. In addition, the FokI single nucleotide polymorphism was also determined. METHODS One hundred and one patients with MM and 101 healthy donors matched for age and sex were enrolled. Molecular VDR typing was performed by means of restriction fragment length polymorphism analysis. RESULTS All cases and controls were in Hardy-Weinberg equilibrium for BsmI, FokI and A-1012G. Significant associations were found between the BsmI bb genotype frequency and MM (P = 0.02) along with Breslow thickness (P = 0.001). This same behaviour was not observed for the FokI or A-1012G polymorphisms. Multivariate logistic regression analysis confirmed these significant results after correction for age, gender, skin type and MM localization. CONCLUSIONS Although the biological meaning of the effects exerted by BsmI polymorphism is still under debate, the statistical association found in the present study suggests that further work should be done to verify this variant as a possible risk marker for MM and its aggressiveness, also considering that the real association may be due to other unknown genes linked to the BsmI b allele.
Collapse
Affiliation(s)
- C Santonocito
- Laboratory of Molecular Biology, Institute of Biochemistry and Clinical Biochemistry, Catholic University, Largo A Gemeli 8, 00168 Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Isambert N, Campone M, Bourbouloux E, Drouin M, Major A, Loadman P, Capizzi R, Grieshaber C, Fumoleau P. Evaluation of the safety of C-1311 administered in a phase I dose-escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2069] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2069 Background: C-1311 is the most active member of a new series of anti-cancer agents, the imidazoacridinones, specially designed compounds developed from research on the structure-activity relationships of other cancer therapies such as the anthracenediones (e.g. mitoxantrone) and the anthracyclines (e.g. doxorubicin). This first-in-man clinical trial was designed to assess the safety profile of C-1311 and determine the recommended dose upon weekly administration for 3 consecutive weeks, within a 28-day cycle. Methods: Patients with advanced solid tumors refractory to conventional therapy were enrolled. The dose escalation scheme was divided into 2 phases: an initial accelerated phase of cohorts of 1 patient at doubling doses and a modified Fibonacci phase of cohorts of 3 pts at 25–33% dose increments. The maximum tolerated dose (MTD) was defined as the dose at which 2/3 or 2/6 pts experienced a dose-limiting toxicity (DLT). The recommended dose (RD) was defined as the dose level below the MTD, confirmed by expansion of the cohort to 9 pts. Results: 16 pts received doses of 15, 30, 60, 120, 240, 480 and 640 mg/m2/wk. The 2 pts treated at 640 mg/m2 experienced a DLT (grade 3 neutropenia preventing the administration of the 2nd and 3rd dose of the first cycle respectively). The RD was defined as 480 mg/m2/wk (cohort of 9 pts). Six additional pts were treated at the RD in an extension study in which one of the first 2 doses was given orally. Overall, 2 serious adverse events have been reported as possibly drug-related, both consisting of post-infusion fever without evidence of infection, resolving within 24 hours. Transient neutropenia was the only recurring grade 3 or 4 drug-related adverse event (AE). Grade 1 or 2 AEs most commonly reported as drug-related were nausea, asthenia, vomiting and diarrhea. Stable disease was observed in 3 patients with advanced malignancy. One pt had a stable course over > 8 cycles, and two had stable courses over 4 cycles. Plasma drug concentrations were linear and proportional to dose. Conclusions: The recommended phase 2 dose of 480 mg/m2, weekly × 3 q 28 days, offers a predictable safety profile and excellent tolerability. [Table: see text]
Collapse
Affiliation(s)
- N. Isambert
- Centre François Leclerc, Dijon, France; Centre René Gauducheau, St. Herblain, France; Xanthus Life Sciences, Montreal, PQ, Canada; University of Bradford, Bradford, United Kingdom; Xanthus Life Sciences, Cambridge, MA
| | - M. Campone
- Centre François Leclerc, Dijon, France; Centre René Gauducheau, St. Herblain, France; Xanthus Life Sciences, Montreal, PQ, Canada; University of Bradford, Bradford, United Kingdom; Xanthus Life Sciences, Cambridge, MA
| | - E. Bourbouloux
- Centre François Leclerc, Dijon, France; Centre René Gauducheau, St. Herblain, France; Xanthus Life Sciences, Montreal, PQ, Canada; University of Bradford, Bradford, United Kingdom; Xanthus Life Sciences, Cambridge, MA
| | - M. Drouin
- Centre François Leclerc, Dijon, France; Centre René Gauducheau, St. Herblain, France; Xanthus Life Sciences, Montreal, PQ, Canada; University of Bradford, Bradford, United Kingdom; Xanthus Life Sciences, Cambridge, MA
| | - A. Major
- Centre François Leclerc, Dijon, France; Centre René Gauducheau, St. Herblain, France; Xanthus Life Sciences, Montreal, PQ, Canada; University of Bradford, Bradford, United Kingdom; Xanthus Life Sciences, Cambridge, MA
| | - P. Loadman
- Centre François Leclerc, Dijon, France; Centre René Gauducheau, St. Herblain, France; Xanthus Life Sciences, Montreal, PQ, Canada; University of Bradford, Bradford, United Kingdom; Xanthus Life Sciences, Cambridge, MA
| | - R. Capizzi
- Centre François Leclerc, Dijon, France; Centre René Gauducheau, St. Herblain, France; Xanthus Life Sciences, Montreal, PQ, Canada; University of Bradford, Bradford, United Kingdom; Xanthus Life Sciences, Cambridge, MA
| | - C. Grieshaber
- Centre François Leclerc, Dijon, France; Centre René Gauducheau, St. Herblain, France; Xanthus Life Sciences, Montreal, PQ, Canada; University of Bradford, Bradford, United Kingdom; Xanthus Life Sciences, Cambridge, MA
| | - P. Fumoleau
- Centre François Leclerc, Dijon, France; Centre René Gauducheau, St. Herblain, France; Xanthus Life Sciences, Montreal, PQ, Canada; University of Bradford, Bradford, United Kingdom; Xanthus Life Sciences, Cambridge, MA
| |
Collapse
|
22
|
Abstract
Celiac disease (CD) is an autoimmune gluten-dependent enteropathy characterized by atrophy of intestinal villi that improves after gluten-free diet (GFD). CD is often associated with extra-intestinal manifestations; among them, several skin diseases are described in CD patients. The present review reports all CD-associated skin manifestations described in the literature and tries to analyze the possible mechanisms involved in this association. The opportunity to evaluate the possible presence of CD in patients affected by skin disorders is discussed.
Collapse
Affiliation(s)
- L Abenavoli
- Institute of Internal Medicine, Catholic University, L.go Gemelli 8, 00168 Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Paradisi A, Capizzi R, Zampetti A, Proietti I, De Simone C, Feliciani C, Amerio PL. Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B. J Infect 2005; 51:e261-4. [PMID: 15936088 DOI: 10.1016/j.jinf.2005.03.012] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2005] [Accepted: 03/22/2005] [Indexed: 10/25/2022]
Abstract
Multifocal cutaneous leishmaniasis (MCL) is an extremely rare disease in South Europe, and it mainly affects immunosuppressed patients. We report a case of MCL in an immunocompetent patient affected by type II diabetes mellitus that clinically presented with three large ulcers on the legs with a non-linear distribution and several months later with an erythematous-crusty lesion on the left cheek. Diagnosis of leishmaniasis due to Leishmania infantum was formulated by PCR analysis. Given the diffuse and wide lesions, the unresponsiveness to previous local and systemic treatments, a parenteral i.v. therapy with liposomal amphotericin B at a dosage of 3mg/kg/day for 5 days was started and then repeated on the 14th and 21st days, leading to a clear improvement in the clinical picture. The different clinical expression and the evolution of leishmaniasis depend on both the parasite subtype and the host's immunity status. L. infantum manifests with an atypical clinical feature more frequently than other species. The differential diagnosis for multiple ulcers must include several skin diseases, such as cutaneous TBC, bacterial ulcers, traumatic ulcers, deep mycoses, and sarcoidosis. However, an MCL should always be considered in subjects coming from endemic areas. In our case, the multifocality, the size of the lesions and the unresponsiveness to other treatment indicate a short course treatment with liposomal B amphotericin that proved to be a suitable alternative to traditional drugs used in MCL.
Collapse
Affiliation(s)
- A Paradisi
- Department of Dermatology, Catholic University of Rome, Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|
24
|
Zampetti A, Feliciani C, Capizzi R, Valenzano F, Manco S, Amerio PL. Scrofuloderma induced by surgical drainage in a joint tuberculosis. Scand J Infect Dis 2005; 37:540-2. [PMID: 16012026 DOI: 10.1080/00365540510037830] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
|
25
|
Capizzi R, Landi F, Milani M, Amerio P. Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator-masked, controlled trial. Br J Dermatol 2004; 151:481-4. [PMID: 15327558 DOI: 10.1111/j.1365-2133.2004.06067.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Combination therapy with antiseptics such as benzoyl peroxide (BP) and topical retinoids is widely used as first-line treatment for acne vulgaris (AV). However, these combinations could have a suboptimal skin tolerability. Recently, a new formulation of hydrogen peroxide (HP) 1% in stabilized cream (Crystacide; Mipharm, Milan, Italy) became available. A previous clinical study has shown that HP cream monotherapy presents a better skin tolerability in comparison with BP in patients with mild AV. OBJECTIVES To evaluate the tolerability and the efficacy of combination therapy with HP cream and adapalene 0.1% gel in comparison with the combination of BP 4% cream and adapalene 0.1% gel in the treatment of mild to moderate AV. METHODS In a randomized, investigator-blinded trial, 52 patients (mean +/- SD age 25 +/- 6 years; 19 men and 33 women) with AV were randomly assigned to HP cream and adapalene gel (group HP + A) or to BP cream and adapalene gel (group BP + A), for eight consecutive weeks. Efficacy was assessed by total (TL), inflammatory (IL) and noninflammatory (NL) lesion counts performed at baseline and weeks 4 and 8. Tolerability was assessed by evaluating skin erythema, burning and dryness at weeks 4 and 8. RESULTS All patients completed the study. At baseline, the mean +/- SD numbers of TL, IL and NL were 44 +/- 9, 25 +/- 7 and 19 +/- 6 in group HP + A and 40 +/- 9, 21 +/- 7 and 19 +/- 9 in group BP + A, respectively. At the end of the treatment period, TL, IL and NL were reduced by 93%, 92% and 95%, respectively, in group HP + A and by 88%, 86% and 90%, respectively, in group BP + A. A significantly (P = 0.0025) greater reduction in NL was observed in group HP + A in comparison with group BP + A. Tolerability was significantly better in group HP + A in comparison with group BP + A (P = 0.02). Skin dryness and burning sensation were more frequent in group BP + A. CONCLUSIONS The combination of adapalene and HP cream is an effective topical treatment regimen in mild to moderate AV. This combination has shown a better tolerability profile in comparison with the combination of BP and adapalene.
Collapse
Affiliation(s)
- R Capizzi
- Clinica Dermatologica, Policlinico Universitario Agostino Gemelli, Rome, Italy
| | | | | | | |
Collapse
|
26
|
Ojetti V, Aguilar Sanchez J, Guerriero C, Fossati B, Capizzi R, De Simone C, Migneco A, Amerio P, Gasbarrini G, Gasbarrini A. High prevalence of celiac disease in psoriasis. Am J Gastroenterol 2003; 98:2574-5. [PMID: 14638373 DOI: 10.1111/j.1572-0241.2003.08684.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
27
|
Ojetti V, Aguilar Sanchez J, Guerriero C, Fossati B, Capizzi R, De Simone C, Migneco A, Amerio P, Gasbarrini G, Gasbarrini A. High prevalence of celiac disease in psoriasis. Am J Gastroenterol 2003. [PMID: 14638373 DOI: 10.1016/s0002-9270(03)01717-9] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
28
|
Guidi B, Diociaiuti A, Capizzi R, Forni F, Scribano D, Vultaggio P, Zappacosta B, Amerio PL. Increased S100B serum levels in diffuse dermatitis. Melanoma Res 2002; 12:633. [PMID: 12459654 DOI: 10.1097/00008390-200212000-00014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Guerriero C, Albanesi C, Girolomoni G, De Simone C, Capizzi R, Amerio P, Tulli A. Huriez syndrome: case report with a detailed analysis of skin dendritic cells. Br J Dermatol 2000; 143:1091-6. [PMID: 11069529 DOI: 10.1046/j.1365-2133.2000.03793.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We report a 60-year-old man with familial scleroatrophic syndrome of Huriez who developed squamous cell carcinomas on the affected skin of the right palm. Immunohistochemical analysis showed a marked reduction in the number of CD1a+, Lag+ and S100+ epidermal Langerhans cells, but not of CD1b+ and factor XIIIa+ dermal dendritic cells, limited to palmoplantar skin. The Langerhans cell depletion was not associated with an abnormal skin content of mRNA for factors involved in Langerhans cell development or recruitment in the epidermis, including granulocyte/macrophage colony-stimulating factor, transforming growth factor-beta1 and macrophage inflammatory protein-3alpha. The results indicate that other as yet unknown mechanisms may account for the reduced number of Langerhans cells in the affected skin of such patients.
Collapse
Affiliation(s)
- C Guerriero
- Department of Dermatology, Catholic University of the Sacred Heart, Largo A.Gemelli 8, 00168 Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
30
|
Capizzi R, Marasca G, De Luca A, Tacconelli E, Cauda R, Rotoli M. Pemphigus vulgaris in a human-immunodeficiency-virus-infected patient. Dermatology 2000; 197:97-8. [PMID: 9711441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
|
31
|
List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90:3364-9. [PMID: 9345018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The aminothiol, amifostine (Ethyol; U.S. Bioscience, West Conshohocken, PA), is a cytoprotective agent that ameliorates the toxicities of anticancer therapy. In vitro, amifostine promotes the formation and survival of primitive hematopoietic progenitors derived from myelodysplastic bone marrow (BM) specimens. To evaluate the hematological effects of amifostine, 18 patients with myelodysplastic syndrome (MDS) and one or more refractory cytopenias received treatment with amifostine in a Phase I/II study. Four cohorts received intravenous treatment with 100, 200, or 400 mg/m2 amifostine three times a week, or 740 mg/m2 weekly for three consecutive weeks followed by 2 weeks observation. Nonresponding patients received a second course of therapy at the next higher dose level depending upon drug tolerance. Bone marrow (BM) progenitor growth was assessed before treatment and after day 21. Diagnoses included refractory anemia (7), refractory anemia with ringed sideroblasts (5), refractory anemia with excess blasts (RAEB) (4), and RAEB-in transformation (RAEB-t) (2). Single- or multi-lineage hematologic responses occurred in 15 patients (83%) treated with the three-times-a-week dose schedule. Fourteen patients had a 50% or greater increase in absolute neutrophil count with amifostine treatment (range, 426 to 11,348/microL). Platelet count increased in 6 (43%) of 14 patients with thrombocytopenia (absolute increase, 16, 000 to 110,000/microL), and 5 of 15 red blood cell transfusion-dependent patients had a 50% of greater reduction in transfusion needs. Assayable hematopoietic progenitors increased in 13 of 15 evaluable patients; including CFU-GEMM (12), BFU-E (8), and CFU-GM (6). Amifostine doses less than or equal to 200 mg/m2 were well tolerated, whereas grade II nausea, vomiting, and fatigue was limiting at higher doses. Three patients with excess blasts before enrollment experienced an increase in BM blast percentage and two patients had evolution to acute leukemia that persisted after treatment withdrawal. We conclude that amifostine administered at doses </=200 mg/m2 three times a week is well tolerated and has hematologic activity in patients with MDS.
Collapse
Affiliation(s)
- A F List
- Section of Hematology/Oncology and the Bone Marrow Transplant Program, The Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724-5024, USA
| | | | | | | | | | | | | |
Collapse
|
32
|
Budd GT, Ganapathi R, Adelstein DJ, Pelley R, Olencki T, Petrus J, McLain D, Zhang J, Capizzi R, Bukowski RM. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997; 80:1134-40. [PMID: 9305715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND To test the hypothesis that the cytoprotectant amifostine attenuates the thrombocytopenia produced by carboplatin, the authors performed a randomized trial comparing treatment with carboplatin alone versus the combination of amifostine and carboplatin. METHODS Patients with refractory or carboplatin-sensitive malignancies were randomized to receive either carboplatin, 500 mg/m2 alone or carboplatin, 500 mg/m2 in conjunction with 2 doses of amifostine of 910 mg/m2 each. RESULTS Fifty-five patients with a variety of malignancies were entered on this study. One patient withdrew from each arm prior to the administration of any therapy, leaving 30 evaluable patients treated with carboplatin alone and 23 treated with the combination of amifostine and carboplatin. For 82 cycles of therapy with amifostine plus carboplatin, the median platelet nadir was 127 x 10(9)/L while the median platelet nadir was 88 x 10(9)/L over the 80 courses of therapy with carboplatin alone (P = 0.023). The median platelet nadir after the first cycle of therapy was 144 x 10(9)/L for patients treated with amifostine plus carboplatin and 85 x 10(9)/L for patients treated with carboplatin alone (P = 0.24). The median survival for 9 patients with advanced nonsmall cell lung carcinoma treated with carboplatin alone was 39 weeks whereas the median survival for 12 such patients treated with amifostine plus carboplatin was 52 weeks (P = 0.116). CONCLUSIONS These data support the hypothesis that amifostine attenuates the myelosuppression of carboplatin. Additional studies of amifostine in combination with carboplatin-containing chemotherapy regimens are warranted.
Collapse
Affiliation(s)
- G T Budd
- Department of Medical Oncology, The Cleveland Clinic Cancer Center, Ohio 44195, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Blanke CD, Kasimis B, Schein P, Capizzi R, Kurman M. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 1997; 15:915-20. [PMID: 9060528 DOI: 10.1200/jco.1997.15.3.915] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE A phase II study to evaluate the response rate and toxicities of a trimetrexate, fluorouracil (5FU), and leucovorin regimen in patients with advanced incurable colorectal cancer. PATIENTS AND METHODS Thirty-six patients with unresectable or metastatic colorectal cancer who had not been treated for advanced disease received the following chemotherapy regimen weekly for six courses every 8 weeks: trimetrexate 110 mg/m2 intravenously (I.V.) on day 1, leucovorin 200 mg/m2 I.V. on day 2 (24 hours later), 5FU 500 mg/m2 on day 2 immediately following leucovorin, and oral leucovorin 15 mg every 6 hours for seven doses starting 6 hours after 5FU. Patients were treated until progression or unacceptable toxicity. RESULTS Thirty patients were assessable for response, and all 36 were assessable for toxicity. Two patients (7%) achieved a complete response (CR) and 13 (43%) a partial response (PR), for an overall response (OR) rate of 50% (95% confidence interval [CI], 32% to 68%). Analysis by intent to treat demonstrated a 42% OR rate (95% CI, 26% to 58%). At final analysis, 16 patients were alive. The median survival duration for the entire cohort was 53.4 weeks. Gastrointestinal toxicity was most common, with 21 patients (58%) having grade 3/4 diarrhea and 12 patients (34%) grade 3/4 nausea. Hematologic toxicity was generally low grade, although two patients died of sepsis. CONCLUSION The combination of trimetrexate with 5FU and leucovorin is active in metastatic colorectal cancer. Gastrointestinal toxicity with this regimen is most prominent, but is manageable.
Collapse
Affiliation(s)
- C D Blanke
- Division of Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
| | | | | | | | | |
Collapse
|
34
|
Capizzi R. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996; 23:2-17. [PMID: 8783661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Administered prior to cytotoxic chemotherapy or radiation, the aminothiol amifostine provides broad-spectrum cytoprotection of various normal tissues without attenuating antitumor response. The basis for the selectivity of action resides in the anabolism of amifostine at the normal tissue site by membrane-bound alkaline phosphatase. Dephosphorylation to the free thiol WR-1065 is followed by rapid uptake into normal tissues by a carrier-mediated facilitated diffusion process. In contrast, uptake into tumor tissues is slow to negligible. Pretreatment with amifostine provides protection of normal tissues from the cytotoxic effects of alkylating agents, organoplatinums, anthracyclines, taxanes, and radiation. Additionally, the mutagenic and carcinogenic effects of these modalities are also attenuated. Preclinical studies show significant protection of marrow progenitor cells that give rise to the red blood cells, white blood cells, and platelets. Protection of kidneys and neural tissues from cisplatin toxicity has been shown, along with protection of the heart, intestinal crypt cells, and pulmonary tissues from chemotherapy and radiation, as well as vasculoconnective and musculoconnective tissue in an irradiated field. Comparative in vitro and in vivo studies using murine and human tumor xenografts show no attenuation of antitumor effects of these same therapies despite the protection of normal organs. The unique preclinical profile of amifostine serves as the basis for the clinical development program for this important new broad-spectrum cytoprotective agent.
Collapse
Affiliation(s)
- R Capizzi
- Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
| |
Collapse
|
35
|
Cagnoni PJ, Jones RB, Bearman SI, Ross M, Hami L, Franklin WA, Capizzi R, Schein PS, Shpall EJ. Use of amifostine in bone marrow purging. Semin Oncol 1996; 23:44-8. [PMID: 8783666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
One of the main obstacles for the use of high-dose chemotherapy with autologous hematopoietic progenitor cell support in the treatment of malignancies is the possibility of reinfusing clonogenic tumor cells with the hematopoietic graft. Purging of the graft with chemicals can reduce the number of tumor cells but can also damage the normal hematopoietic progenitors. Preclinical studies showed that the phosphorylated sulfhydryl compound amifostine (WR-2721) can protect normal hematopoietic progenitors from damage from alkylating agents. We conducted a randomized clinical trial in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease undergoing autologous bone marrow transplant. In this study, patients were randomized to have their bone marrow purged with 4-hydroperoxycyclophosphamide (4-HC) with (arm A) or without (arm B) amifostine. The percentage of colony-forming unit granulocyte-macrophages recovered after purging was higher in the amifostine arm, both in patients with breast cancer and in those with lymphoma, although this difference was not statistically significant. In addition, the time to engraftment was significantly shorter in the amifostine arm in both cohorts. We showed that pretreatment of bone marrow with amifostine prior to purging with 4-HC can protect normal hematopoietic progenitors from damage by 4-HC. This resulted in shorter engraftment rates and less need for supportive care.
Collapse
Affiliation(s)
- P J Cagnoni
- University of Colorado Bone Marrow Transplant Program, University of Colorado Cancer Center, Denver 80262, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
|
37
|
Rotoli M, Capizzi R, Carlesimo F, Celleno L, Cavalieri S. [Cutaneous tuberculosis: a case of difficult classification]. Recenti Prog Med 1995; 86:21-4. [PMID: 7709036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We describe a case of cutaneous tuberculosis in a 25-year-old Philippine man. Erythematous papulo-nodular lesions, measuring 0.5 to 1 cm, were present on lower limbs; a 2 cm nodule was located on the left flank. The examination of the skin biopsy showed the presence of a superficial and deep perivascular dermatitis with histiocytes, lymphocytes and plasma cells. Ziehl-Nielsen stain for mycobacterium were negative, while the cultural examination led to the isolation of M. tuberculosis. Direct smear and cultural examination of sputum for M. tuberculosis were negative; chest and skeletal roentgenograms, syphilis and HIV infection serology, haematological and hematochemical examinations and urinalysis were negative. Specific treatment with isoniazid, rifampin and ofloxacin led to a rapid remission of cutaneous lesions. This case was particularly difficult to classify, but the Authors think it would be considered a tuberculid.
Collapse
Affiliation(s)
- M Rotoli
- Clinica Dermatologica, Università Cattolica del Sacro Cuore, Roma
| | | | | | | | | |
Collapse
|
38
|
Rotoli M, La Parola IL, Capizzi R, Altomonte L, Mirone L, Magarò M. [Yellow nail syndrome: description of a case and review of the associated pathology]. Recenti Prog Med 1990; 81:149-51. [PMID: 2113700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The AA. report a case of yellow nail syndrome associated with rheumatoid arthritis and monoclonal gammopathy (IgG-lambda). Because of the great variety of the diseases associated with this syndrome, the AA. suggest to control patients periodically to verify the probable appearance of other clinical manifestations.
Collapse
Affiliation(s)
- M Rotoli
- Istituto di Clinica dermatologica, Università Cattolica del Sacro Cuore, Roma
| | | | | | | | | | | |
Collapse
|
39
|
Tulli A, Biele MM, Petitti G, Rossi GF, Capizzi R. [Possible use of interferon in cutaneous sclerosis]. GIORN ITAL DERMAT V 1988; 123:383-4. [PMID: 3225003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
40
|
Tulli A, Biele MM, Capizzi R. [A possible visceralization in a case of cutaneous T cell lymphoma under treatment with recombinant interferon alfa 2]. GIORN ITAL DERMAT V 1988; 123:262. [PMID: 3264816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
41
|
Rotoli M, Zamparelli F, Giorgi MN, Capizzi R. [Limitations of health information on AIDS as a means of prevention]. GIORN ITAL DERMAT V 1988; 123:55-7. [PMID: 3417338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
42
|
Rotoli M, Zamparelli F, Capizzi R, Rusciani L. [Health education in sexually transmitted diseases in Italy]. GIORN ITAL DERMAT V 1987; 122:467-70. [PMID: 3679302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
43
|
Capizzi R, Cacciaguerra MG, Guerriero G, Tulli A. [Stevens-Johnson syndrome caused by isoxicam]. GIORN ITAL DERMAT V 1986; 121:461-2. [PMID: 3557542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
44
|
Rotoli M, Capizzi R, Tulli A. [Association of erosive lichen of the mucosa, chronic hepatopathy of uncertain classification, bullous pemphigoid]. GIORN ITAL DERMAT V 1986; 121:310. [PMID: 3530989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
45
|
Rotoli M, Capizzi R, Tulli A. [Onychopathy due to Penicillium (green nails): topical treatment with econazole nitrate]. GIORN ITAL DERMAT V 1982; 117:XV-XVII. [PMID: 7187389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
46
|
Prusoff WH, Ward DC, Lin TS, Chen MS, Shaiu GT, Chai C, Lentz E, Capizzi R, Idriss J, Ruddle NH, Black FL, Kumari HL, Albert D, Bhatt PN. Recent studies on the antiviral and biochemical properties of 5-halo-5'-amino-deoxyribonucleosides. Ann N Y Acad Sci 1977; 284:335-41. [PMID: 212979 DOI: 10.1111/j.1749-6632.1977.tb21968.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
47
|
Bertino JR, Hryniuk WM, Capizzi R. Prediction of methotrexate responsiveness of tumors in man. Natl Cancer Inst Monogr 1971; 34:179. [PMID: 5291100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
48
|
|